IQVIA Teams Up with Flagship to Advance Biopharma Innovation

IQVIA, a leading global provider of clinical research services, commercial insights and healthcare intelligence, and Flagship Pioneering, the bioplatform innovation company, announced a strategic collaboration to accelerate the development of breakthrough life sciences companies. The collaboration will help the Flagship ecosystem of biopharma companies accelerate innovation by offering access to IQVIA's comprehensive capabilities including unparalleled information assets, analytics and domain expertise across the drug development life cycle from discovery through early development and commercialization.

The collaboration will utilize IQVIA's cutting-edge technologies in the areas of artificial intelligence, analytics and clinical trial design and execution to create a more seamless, efficient and effective approach to drug development and early commercial viability for Flagship's ecosystem of companies. The work will center on three service areas: drug development strategy and analytics, clinical development, and asset valuation and due diligence.

"Working with Flagship Pioneering to foster the development of emerging biopharma companies that will advance the development of life-saving therapies fits squarely within IQVIA's mission to accelerate innovations for a healthier world and bring better treatments to patients faster," said Rob Kotchie, president of Real World Solutions at IQVIA. "We're excited to be a partner to the type of brave and bold thinking at Flagship Pioneering that will secure a healthier and more sustainable future."

"This collaboration brings enormous value to our platform companies by providing them the potential to greatly expand their reach and impact," said David Khougazian, Executive Partner, Flagship Pioneering. "By using IQVIA's robust data infrastructure and analytics capabilities alongside Flagship's pioneering bioplatforms, this collaboration is poised to positively impact the ability of our companies to accelerate their platform capabilities and drive value creation for life sciences."